ClinicalTrials.gg
CompletedNCT02854527Updated Nov 7, 2023Results posted

Transporter Cocktail Mutual Interaction

A Phase 1 interventional study of Digoxin and Furosemide in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Main objective is to investigate mutual pharmacokinetic drug-drug interactions of digoxin, furosemide, metformin, and rosuvastatin when given all together as a cocktail

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the investigator's assessment, based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 55 years (incl.)
  • (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice and local legislation

Exclusion criteria

Exclusion criteria:

  • Any finding in the medical examination (including BP, PR or ) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to the trial medication or its , sulphonamides, or cardiac glycosides)
  • Use of drugs within 30 days prior to administration of trial medication that might reasonably influence the results of the trial (incl. /QTc interval prolongation (corrected Q-T interval)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on specified trial days
  • Alcohol abuse (consumption of more than 30 g per day)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

In addition, the following trial-specific exclusion criteria apply:

  • Hypokalemia, hypomagnesemia, or hypercalcemia
  • PQ ( (time between the onset of the P wave (atrial activity) and the QRS complex (ventricular activity)) interval greater than 220 ms in the ECG at screening
  • Myopathy
  • Hereditary galactose or fructose intolerance, lactase deficiency, or glucose-galactose malabsorption
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    R1 (Reference 1) Digoxin

    1 tablet (0.25 mg) digoxin as single dose

    Drug: Digoxin

  • Experimental
    R2 Furosemide

    0.1 mL (1 mg) furosemide oral solution as single dose

    Drug: Furosemide

  • Experimental
    R3 Metformin hydrochloride

    0.1 mL (10 mg) metformin oral solution as single dose

    Drug: Metformin

  • Experimental
    R4 Rosuvastatin

    1 tablet (10 mg) rosuvastatin as single dose

    Drug: Rosuvastatin

  • Experimental
    T (Test)

    1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')

    Drug: Digoxin · Drug: Furosemide · Drug: Metformin hydrochloride · Drug: Rosuvastatin

Interventions

  • single dose

  • single dose

  • single dose

  • single dose

  • 0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)

  • 1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)

  • 10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)

  • 10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)

06

What researchers measure

Primary outcomes

  1. Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz)

    Area under the concentration-time curve of digoxin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error. CI - confidence interval, gMean - geometric mean.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration

  2. Maximum Concentration of Digoxin (Cmax)

    This outcome measure presents the maximum measured concentration of digoxin in plasma (Cmax). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration

  3. Area Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz)

    Area under the concentration-time curve of furosemide in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration

  4. Maximum Concentration of Furosemide (Cmax)

    This outcome measure presents the maximum measured concentration of furosemide in plasma (Cmax). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration

  5. Area Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz)

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration

  6. Maximum Concentration of Metformin (Cmax)

    This outcome measure presents the maximum measured concentration of metformin in plasma (Cmax). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration

  7. Area Under the Curve of Rosuvastatin From 0 to Last Quantifiable Data Point (AUC 0-tz)

    Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration

  8. Maximum Concentration of Rosuvastatin (Cmax)

    This outcome measure presents the maximum measured concentration of rosuvastatin in plasma (Cmax). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration

Secondary outcomes

  1. Area Under the Curve of Digoxin From 0 Extrapolated to Infinity (AUC 0-∞)

    Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration

  2. Area Under the Curve of Furosemide From 0 Extrapolated to Infinity (AUC 0-∞)

    Area under the concentration-time curve of furosemide in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration

  3. Area Under the Curve of Metformin From 0 Extrapolated to Infinity (AUC 0-∞)

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration

  4. Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC 0-∞)

    Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.

    Time frame: Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration

07

Results

Posted Aug 6, 2018

Participant flow

Participant flow — Overall Study
MilestoneABECD (R1->R2->T->R3->R4)AEBDC (R1->T->R2->R4->R3)BACED (R2->R1->R3->T->R4)BCADE (R2->R3->R1->R4->T)CBDAE (R3->R2->R4->R1->T)CDBEA (R3->R4->R2->T->R1)DCEBA (R4->R3->T->R2->R1)DECAB (R4->T->R3->R1->R2)EADBC (T->R1->R4->R2->R3)EDACB (T->R4->R1->R3->R2)
Started3333333333
Received r13332233333
Received r23333333333
Received r33332333333
Received r43332333333
Received t3332233333
Completed3332233333
Not completed0001100000
Withdrew: Adverse event0000100000
Withdrew: Lost to follow-up0001000000

Outcome measures

PrimaryArea Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz)

Area under the concentration-time curve of digoxin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error. CI - confidence interval, gMean - geometric mean.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Reported as:
Geometric mean · nanomole hour per liter (nmol·h/L)
Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz)
nanomole hour per liter (nmol·h/L)Test Cocktail (T)Digoxin (R1)
Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz)11.549 ± 1.05311.981 ± 1.053
Statistical analysis
  • Test Cocktail (T) vs Digoxin (R1) · ANOVA · Adjusted geometric mean ratio (t/r1) (%): 96.39 · 90% CI 88.22 to 105.33Least square estimates of log-transformed PK endpoint for T and R1 were back transformed to original scale to get adjusted gMean ratio (T/R1) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
PrimaryMaximum Concentration of Digoxin (Cmax)

This outcome measure presents the maximum measured concentration of digoxin in plasma (Cmax). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Reported as:
Geometric mean · nanomole per liter (nmol/L)
Maximum Concentration of Digoxin (Cmax)
nanomole per liter (nmol/L)Test Cocktail (T)Digoxin (R1)
Maximum Concentration of Digoxin (Cmax)1.262 ± 1.0471.355 ± 1.047
Statistical analysis
  • Test Cocktail (T) vs Digoxin (R1) · ANOVA · Adjusted geometric mean ratio (t/r1) (%): 93.17 · 90% CI 83.49 to 103.97Least square estimates of log-transformed PK endpoint for T and R1 were back transformed to original scale to get adjusted gMean ratio (T/R1) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
PrimaryArea Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz)

Area under the concentration-time curve of furosemide in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration
Reported as:
Geometric mean · nmol·h/L
Area Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz)
nmol·h/LTest Cocktail (T)Furosemide (R2)
Area Under the Curve of Furosemide From 0 to Last Quantifiable Data Point (AUC 0-tz)163.614 ± 1.039159.434 ± 1.038
Statistical analysis
  • Test Cocktail (T) vs Furosemide (R2) · ANOVA · Adjusted geometric mean ratio (t/r2) (%): 102.62 · 90% CI 93.82 to 112.25Least square estimates of log-transformed PK endpoint for T and R2 were back transformed to original scale to get adjusted gMean ratio (T/R2) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
PrimaryMaximum Concentration of Furosemide (Cmax)

This outcome measure presents the maximum measured concentration of furosemide in plasma (Cmax). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration
Reported as:
Geometric mean · nmol/L
Maximum Concentration of Furosemide (Cmax)
nmol/LTest Cocktail (T)Furosemide (R2)
Maximum Concentration of Furosemide (Cmax)86.275 ± 1.04682.990 ± 1.044
Statistical analysis
  • Test Cocktail (T) vs Furosemide (R2) · ANOVA · Adjusted geometric mean ratio (t/r2) (%): 103.96 · 90% CI 93.60 to 115.46Least square estimates of log-transformed PK endpoint for T and R2 were back transformed to original scale to get adjusted gMean ratio (T/R2) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
PrimaryArea Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz)

Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration
Reported as:
Geometric mean · nmol·h/L
Area Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz)
nmol·h/LTest Cocktail (T)Metformin Hydrochloride (R3)
Area Under the Curve of Metformin From 0 to Last Quantifiable Data Point (AUC 0-tz)1283.797 ± 1.0341316.790 ± 1.033
Statistical analysis
  • Test Cocktail (T) vs Metformin Hydrochloride (R3) · ANOVA · Adjusted geometric mean ratio (t/r3) (%): 97.49 · 90% CI 93.54 to 101.61Least square estimates of log-transformed PK endpoint for T and R3 were back transformed to original scale to get adjusted gMean ratio (T/R3) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
PrimaryMaximum Concentration of Metformin (Cmax)

This outcome measure presents the maximum measured concentration of metformin in plasma (Cmax). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration
Reported as:
Geometric mean · nmol/L
Maximum Concentration of Metformin (Cmax)
nmol/LTest Cocktail (T)Metformin Hydrochloride (R3)
Maximum Concentration of Metformin (Cmax)225.156 ± 1.045229.171 ± 1.044
Statistical analysis
  • Test Cocktail (T) vs Metformin Hydrochloride (R3) · ANOVA · Adjusted geometric mean ratio (t/r3) (%): 98.25 · 90% CI 91.85 to 105.09Least square estimates of log-transformed PK endpoint for T and R3 were back transformed to original scale to get adjusted gMean ratio (T/R3) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
PrimaryArea Under the Curve of Rosuvastatin From 0 to Last Quantifiable Data Point (AUC 0-tz)

Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC 0-tz). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Reported as:
Geometric mean · nmol·h/L
Area Under the Curve of Rosuvastatin From 0 to Last Quantifiable Data Point (AUC 0-tz)
nmol·h/LTest Cocktail (T)Rosuvastatin (R4)
Area Under the Curve of Rosuvastatin From 0 to Last Quantifiable Data Point (AUC 0-tz)81.925 ± 1.07078.016 ± 1.069
Statistical analysis
  • Test Cocktail (T) vs Rosuvastatin (R4) · ANOVA · Adjusted geometric mean ratio (t/r4) (%): 105.01 · 90% CI 96.39 to 114.40Least square estimates of log-transformed PK endpoint for T and R4 were back transformed to original scale to get adjusted gMean ratio (T/R4) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
PrimaryMaximum Concentration of Rosuvastatin (Cmax)

This outcome measure presents the maximum measured concentration of rosuvastatin in plasma (Cmax). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Reported as:
Geometric mean · nmol/L
Maximum Concentration of Rosuvastatin (Cmax)
nmol/LTest Cocktail (T)Rosuvastatin (R4)
Maximum Concentration of Rosuvastatin (Cmax)8.135 ± 1.0747.801 ± 1.073
Statistical analysis
  • Test Cocktail (T) vs Rosuvastatin (R4) · ANOVA · Adjusted geometric mean ratio (t/r4) (%): 104.28 · 90% CI 94.95 to 114.53Least square estimates of log-transformed PK endpoint for T and R4 were back transformed to original scale to get adjusted gMean ratio (T/R4) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
SecondaryArea Under the Curve of Digoxin From 0 Extrapolated to Infinity (AUC 0-∞)

Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Reported as:
Geometric mean · nmol·h/L
Area Under the Curve of Digoxin From 0 Extrapolated to Infinity (AUC 0-∞)
nmol·h/LTest Cocktail (T)Digoxin (R1)
Area Under the Curve of Digoxin From 0 Extrapolated to Infinity (AUC 0-∞)17.668 ± 1.03918.303 ± 1.039
Statistical analysis
  • Test Cocktail (T) vs Digoxin (R1) · ANOVA · Adjusted geometric mean ratio (t/r1) (%): 96.53 · 90% CI 92.08 to 101.20Least square estimates of log-transformed PK endpoint for T and R1 were back transformed to original scale to get adjusted gMean ratio (T/R1) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
SecondaryArea Under the Curve of Furosemide From 0 Extrapolated to Infinity (AUC 0-∞)

Area under the concentration-time curve of furosemide in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00 and 24:00 after drug administration
Reported as:
Geometric mean · nmol·h/L
Area Under the Curve of Furosemide From 0 Extrapolated to Infinity (AUC 0-∞)
nmol·h/LTest Cocktail (T)Furosemide (R2)
Area Under the Curve of Furosemide From 0 Extrapolated to Infinity (AUC 0-∞)156.382 ± 1.049160.551 ± 1.052
Statistical analysis
  • Test Cocktail (T) vs Furosemide (R2) · ANOVA · Adjusted geometric mean ratio (t/r2) (%): 97.40 · 90% CI 90.87 to 104.41Least square estimates of log-transformed PK endpoint for T and R2 were back transformed to original scale to get adjusted gMean ratio (T/R2) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
SecondaryArea Under the Curve of Metformin From 0 Extrapolated to Infinity (AUC 0-∞)

Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00 and 48:00 after drug administration
Reported as:
Geometric mean · nmol·h/L
Area Under the Curve of Metformin From 0 Extrapolated to Infinity (AUC 0-∞)
nmol·h/LTest Cocktail (T)Metformin Hydrochloride (R3)
Area Under the Curve of Metformin From 0 Extrapolated to Infinity (AUC 0-∞)1290.928 ± 1.0331324.078 ± 1.033
Statistical analysis
  • Test Cocktail (T) vs Metformin Hydrochloride (R3) · ANOVA · Adjusted geometric mean ratio (t/r3) (%): 97.50 · 90% CI 93.58 to 101.58Least square estimates of log-transformed PK endpoint for T and R3 were back transformed to original scale to get adjusted gMean ratio (T/R3) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).
SecondaryArea Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC 0-∞)

Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞). Standard error presented is actually geometric standard error.

Time frame:
Blood sampling at 2:00 (hour: minute) before drug administration, 0:20, 0:40, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00, 72:00 and 96:00 after drug administration
Reported as:
Geometric mean · nmol·h/L
Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC 0-∞)
nmol·h/LTest Cocktail (T)Rosuvastatin (R4)
Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC 0-∞)97.385 ± 1.07290.479 ± 1.069
Statistical analysis
  • Test Cocktail (T) vs Rosuvastatin (R4) · ANOVA · Adjusted geometric mean ratio (t/r4) (%): 107.63 · 90% CI 97.04 to 119.39Least square estimates of log-transformed PK endpoint for T and R4 were back transformed to original scale to get adjusted gMean ratio (T/R4) and its 2-sided 90% CI. Standard deviation is intra-individual geometric coefficient of variation (%).

Adverse events

Collected over Adverse events (AEs) occurring up to 192 hours after intake of trial drug administration in each treatment period were assigned to treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Digoxin (R1)—1/28 (3.6%)0/28 (0%)
Furosemide (R2)—0/30 (0%)0/30 (0%)
Metformin Hydrochloride (R3)—0/29 (0%)1/29 (3.4%)
Rosuvastatin (R4)—0/29 (0%)1/29 (3.4%)
Test Cocktail (T)—0/28 (0%)3/28 (10.7%)
Most frequent serious events
Most frequent serious events
EventDigoxin (R1)Furosemide (R2)Metformin Hydrochloride (R3)Rosuvastatin (R4)Test Cocktail (T)
Exposure to toxic agentInjury, poisoning and procedural complications1/280/300/290/290/28
Most frequent other events
Most frequent other events
EventDigoxin (R1)Furosemide (R2)Metformin Hydrochloride (R3)Rosuvastatin (R4)Test Cocktail (T)
HeadacheNervous system disorders0/280/301/291/293/28

Baseline characteristics

The randomised set (RS) included all randomised subjects, whether treated or not

Age, Continuous
Age, Continuous(Years)ABECD (R1->R2->T->R3->R4)AEBDC (R1->T->R2->R4->R3)BACED (R2->R1->R3->T->R4)BCADE (R2->R3->R1->R4->T)CBDAE (R3->R2->R4->R1->T)CDBEA (R3->R4->R2->T->R1)DCEBA (R4->R3->T->R2->R1)DECAB (R4->T->R3->R1->R2)EADBC (T->R1->R4->R2->R3)EDACB (T->R4->R1->R3->R2)Total
Mean26.7 ± 2.528.7 ± 8.141.3 ± 15.842.0 ± 5.332.3 ± 9.045.7 ± 7.230.3 ± 6.433.0 ± 9.640.3 ± 7.534.3 ± 7.235.5 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)ABECD (R1->R2->T->R3->R4)AEBDC (R1->T->R2->R4->R3)BACED (R2->R1->R3->T->R4)BCADE (R2->R3->R1->R4->T)CBDAE (R3->R2->R4->R1->T)CDBEA (R3->R4->R2->T->R1)DCEBA (R4->R3->T->R2->R1)DECAB (R4->T->R3->R1->R2)EADBC (T->R1->R4->R2->R3)EDACB (T->R4->R1->R3->R2)Total
Female00000000000
Male333333333330
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Nov 2016, 2 months.

Results were first posted in Aug 2018, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2016
First posted
Aug 3, 2016
StartActual
Aug 22, 2016
Primary completionActual
Nov 11, 2016
CompletionActual
Nov 19, 2016
Results first posted
Aug 6, 2018
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02854527
Responsible party
Sponsor
First posted
Aug 3, 2016
Start date
Aug 22, 2016
Primary completion
Nov 11, 2016
Completion
Nov 19, 2016
Results posted
Aug 6, 2018
Last update
Nov 7, 2023

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Digoxin · Furosemide · Metformin · Rosuvastatin

Start the discussion